Japanese Health Care Reform Is Coming -By P Reed Maurer

4 August 1996

In April 1997, Japan's Ministry of Health and Welfare will implement health care reforms that will change the paradigm of medical care delivery and reimbursement in that country. In this article, I will describe the driving forces behind the reform movement, enumerate the alternatives which are under consideration and forecast the likely outcome.

It is naive to assume that the movement for health care reform in Japan is driven solely by the need to reduce costs. This society spends 7% of its national income on health care, about half the US level; costs are not out of control.

However, as medical expenses rise faster than income, the government and other insurers are concerned about the growth rate of health care costs. As Japan's population ages more rapidly than any other society in history, cost increases are inevitable. Another pressure factor is the rising expectation of quality care by young and old alike. Quality care is more expensive.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight